Global Coronary Stents Market

Global Coronary Stents Market Size Insights Forecasts to 2035

• The Global Coronary Stents Market Size Was valued at USD 6.53 Billion in 2024
• The Global Coronary Stents Market Size is Expected to Grow at a CAGR of around 6.94% from 2025 to 2035
• The Worldwide Coronary Stents Market Size is Expected to Reach USD 13.66 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Coronary Stents Market Size Was Worth Around USD 6.53 Billion In 2024 And Is Predicted To Grow To Around USD 13.66 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 6.94% From 2025 To 2035. The demand for coronary stents has increased because more people develop coronary artery disease (CAD) which results from aging and poor dietary habits and inactive life patterns.

 

Market Overview

The Global Coronary Stents Market Size refers to the sector of medical devices that provides support to narrowed or blocked coronary arteries, ensuring proper blood flow and preventing restenosis after angioplasty. The medical field uses three types of coronary stents which are drug-eluting stents and bare-metal stents and bioresorbable vascular scaffolds to treat patients who have cardiovascular diseases that include coronary artery disease. The market experiences growth because more people develop cardiovascular disorders and the elderly population increases and people learn more about the importance of early medical diagnosis and treatment. The implementation of new stent materials together with advanced drug coatings and delivery systems leads to better patient results and better overall efficiency during medical procedures. The major markets use government initiatives together with healthcare infrastructure investments and reimbursement policies to increase the usage of coronary stents. The market experiences continuous growth because public health programs which promote cardiovascular disease management and preventive care create new opportunities in both developed and emerging markets.

 

Report Coverage

This research report categorizes the Coronary Stents Market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Coronary Stents market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Coronary Stents market. 

 

Driving Factors

The development of bioresorbable stents which dissolve after their job is done represents a major advancement in coronary stent technology because it eliminates the need for patients to have permanent implants which would increase their chances of experiencing late stent thrombosis. The National Medical Products Administration in China approved MicroPort Scientific Corporation's Firesorb® bioresorbable cardiac stent in July 2024. The stent showed outstanding clinical study results because it had a low rate of target lesion failure and thrombosis events. Drug-coated balloons work as a new technology which enables direct drug delivery to arteries while avoiding permanent device attachment, making them suitable for treating complex lesions and patients who face high risks of restenosis. The technologies work to achieve better patient results by decreasing long-term health issues and improving blood vessel repair processes and providing customized treatment methods for coronary procedures.

 

Restraining Factors

The Global Coronary Stents Market Size faces restraints from high device costs, risk of complications like restenosis or thrombosis, stringent regulatory approvals, and limited accessibility in low-income regions, which may slow market growth.

 

Market Segmentation

The Coronary Stents market share is classified into type and end use.

 

• The drug eluting segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.           

Based on the type, the coronary stents market is divided into BMS, BVS, and drug eluting. Among these, the drug eluting segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Drug-eluting stents (DES) represent a major progress in coronary artery disease therapy because they help reduce the chances of patients developing restenosis after stent placement. The stents feature a drug coating which delivers its medication progressively to prevent abnormal tissue development around the stent. The drug coating helps decrease both inflammation and scar tissue development which leads to better long-term results with reduced medical problems. The Journal of the Society for Cardiovascular Angiography & Interventions published an article in May 2023 about the SPIRIT 48 trial which tested Abbott's XIENCE Skypoint 48 drug-eluting stents on patients with long de novo coronary lesions. The trial reported a target lesion failure rate of 5.7% and a high device success rate of 97.2% which proved the stent demonstrated both safety and effectiveness.         

• The outpatient facilities segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.     

Based on the end use, the coronary stents market is divided into inpatient and outpatient facilities. Among these, the outpatient facilities segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The number of elective stent placements in less invasive settings has increased because doctors now perform these procedures more frequently. The development of drug-eluting stents and bioresorbable scaffolds has made it possible to conduct most coronary interventions in outpatient facilities. Outpatient care services show growing usage because these procedures require brief recovery periods and create lower expenses while only requiring patients to spend minimal time away from their regular activities. The American College of Cardiology 73rd Annual Scientific Session held in April 2024 presented research which showed that same-day discharge after elective PCI procedures has become both safe and common because hospitals now experience low readmission rates for this practice.   

 

Regional Segment Analysis of the Coronary Stents Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the Coronary Stents market over the predicted timeframe.

North America is anticipated to hold the largest share of the coronary stents market over the predicted timeframe. The high rates of cardiovascular diseases together with medical technology progress and existing healthcare systems create a healthcare system demand. The senior population combined with increased healthcare knowledge and effective reimbursement systems drives the demand. A March 2024 article in WIREs Nanomedicine and Nanobiotechnology discussed the significant role of nanotechnology in enhancing coronary stents, which had been vital in treating atherosclerosis. The review highlighted advancements such as nanocoating's, which improved drug delivery and stent properties, as well as various nanoparticle-based formulations for local drug delivery. The study examined how medical devices using nanoparticle delivery systems can lead to two different types of health problems, which include cytotoxic effects and hypersensitivity reactions.

 

Asia-Pacific is expected to grow at a rapid CAGR in the coronary stents market during the forecast period. The rising cardiovascular disease incidence and better healthcare access and higher disposable incomes in China and India drive the current market development. The market expands because of technological progress and the presence of affordable stents which include drug-eluting stents. Researchers from a January 2024 study published in Nature Communications developed a drug-free stent coating which uses recombinant humanized type III collagen and shows better endothelialization and lower in-stent restenosis rates in animal studies. The new coating shows both anticoagulation and anti-inflammatory effects which makes it a potential replacement for conventional drug-eluting stents.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Coronary Stents market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Abbott
• Medtronic
• Boston Scientific Corporation
• Terumo Corporation
• B Braun SE
• Biotronik
• Stentys SA
• MicroPort Scientific Corporation
• C. R. Bard, Inc.
• Cook Medical

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In September 2024, Uppsala University had launched a flexible stent to reduce complications in coronary artery surgery. The Infinity-Swedeheart study, involving 2,400 patients from 20 Swedish hospitals, compared this new stent to the conventional Resolute Onyx stent. This innovation had the potential to improve patient recovery and long-term success rates in cardiac surgery.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Coronary Stents market based on the below-mentioned segments: 

 

Global Coronary Stents Market, By Type 

• BMS
• BVS
• Drug Eluting

 

Global Coronary Stents Market, By End Use

• Inpatient
• Outpatient Facilities

 

Global Coronary Stents Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the CAGR of the Coronary Stents market over the forecast period?

A: The global Coronary Stents market is projected to expand at a CAGR of 6.94% during the forecast period.

 

2. What is the market size of the Coronary Stents market?

A: the global coronary stents market size is estimated to grow from USD 6.53 billion in 2024 to USD 13.66 billion by 2035, at a CAGR of 6.94% during the forecast period 2025-2035.   

 

3. Which region holds the largest share of the Coronary Stents market?

A: North America is anticipated to hold the largest share of the Coronary Stents market over the predicted timeframe.

 

4. Who are the top 10 companies operating in the global Coronary Stents market?

A: Abbott, Medtronic, Boston Scientific Corporation, Terumo Corporation, B Braun SE, Biotronik, Stentys SA, MicroPort Scientific Corporation, C. R. Bard, Inc., Cook Medical, and Others.

 

5. What are the market trends in the Coronary Stents market?

A: The coronary stents market shows key trends which include increased usage of drug-eluting stents and bioresorbable stents together with technological developments that include nanocoatings and the rise of minimally invasive procedures and the rising number of cardiovascular patients and the healthcare programs which governments implement to support their citizens.